TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10973748

Group type: EXPERIMENTAL
Intervention: Quality circles intervention in intervention hospitals
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Quality circles intervention
Number of subjects: 8
Study: 8983091

Group type: EXPERIMENTAL
Intervention: Intranasal cholecystokinin‐8 (CCK) 10 micrograms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous cholecystokinin‐8 (CCK) 0.25 micrograms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous cholecystokinin‐8 (CCK) 2.5 micrograms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intranasal cholecystokinin‐8 (CCK)
Number of subjects: 20
Study: 1458715

Group type: EXPERIMENTAL
Intervention: Flurbiprofen-SR 200 mg
Number of subjects: 85

Group type: COMPARATOR
Intervention: Diclofenac Sodium-SR 100 mg
Number of subjects: 85
Study: 6724532

Group type: EXPERIMENTAL
Intervention: Pyridoxine (vitamin B6)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 31536957

Group type: EXPERIMENTAL
Intervention: Usual care arm of the Pain Program for Active Coping and Training (PPACT) study, involving opioid treatment under monitoring.
Number of subjects: 97
Study: 28753781

Group type: EXPERIMENTAL
Intervention: ERSPC Risk Calculator 3 (RC3)
Number of subjects: 2270

Group type: EXPERIMENTAL
Intervention: ERSPC Risk Calculator 4 (RC4)
Number of subjects: 2270

Group type: COMPARATOR
Intervention: PSA and Digital Rectal Examination (DRE)
Number of subjects: 2270
Study: 27106691

Group type: EXPERIMENTAL
Intervention: F0.5 group (0.5 μg.kg(‐1) fentanyl)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: F1.0 group (1.0 μg.kg(‐1) fentanyl)
Number of subjects: 90
Study: 24598244

Group type: EXPERIMENTAL
Intervention: GAD65 vaccination with GAD-alum (twice subcutaneously at intervals of 4 weeks)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: GAD65 vaccination with GAD-alum
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 21680782

Group type: COMPARATOR
Intervention: Subcutaneous or intramuscular PEG‐IFN beta‐1a (63, 125, or 188 µg)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Subcutaneous PEG‐IFN beta‐1a dosed once every 2 or 4 weeks
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: PEG‐IFN beta‐1a
Number of subjects: 129

Group type: COMPARATOR
Intervention: Intramuscular unmodified IFN beta‐1a 30 µg
Number of subjects: 129
Study: 20564242

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 53
Study: 18093289

Group type: EXPERIMENTAL
Intervention: Internet group (n = 111)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Usual care group (n = 110)
Number of subjects: 221
Study: 15129394

Group type: EXPERIMENTAL
Intervention: Tai Chi Chun (TCC) exercise for 45 minutes a day, 5 days a week, for 12 months
Number of subjects: 132

Group type: COMPARATOR
Intervention: Sedentary lifestyle (control group)
Number of subjects: 132
Study: 16201177

Group type: EXPERIMENTAL
Intervention: Single dose of ciprofloxacin (0.5 g) and metronidazole (0.4 g)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Combination of ciprofloxacin (0.5 g) and metronidazole (0.4 g) twice a day for 3 days
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo (Vit C) tablet twice a day for 3 days
Number of subjects: 192
Study: 9582043

Group type: EXPERIMENTAL
Intervention: Intervention hospitals (clinician education by local opinion leaders)
Number of subjects: 5347

Group type: COMPARATOR
Intervention: Control hospitals (mailed performance feedback)
Number of subjects: 5347

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 5347
Study: 7759964

Group type: EXPERIMENTAL
Intervention: Cimetidine (28 non‐smokers and 8 smokers)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth (27 non‐smokers and 10 smokers)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Sucralfate (21 non‐smokers and 10 smokers)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (non‐smokers)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (smokers)
Number of subjects: 104
Study: 3052691

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg daily for 3 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 3 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg daily for 6 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 6 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tamoxifen for cyclical pain
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tamoxifen for non-cyclical pain
Number of subjects: 60
Study: 31134226

Group type: EXPERIMENTAL
Intervention: Glass Carbomer (GC)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Resin‐modified glass‐ionomer cement (RMGIC)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Composite resin (CR)
Number of subjects: 162
Study: 29412185

Group type: COMPARATOR
Intervention: Day Surgery setting
Number of subjects: 112

Group type: COMPARATOR
Intervention: Outpatient setting
Number of subjects: 112

Group type: COMPARATOR
Intervention: Outpatient setting (patients over 65 years)
Number of subjects: 112
Study: 27592112

Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy (NAC)
Number of subjects: 188
Study: 24797871

Group type: EXPERIMENTAL
Intervention: PCP counseling
Number of subjects: 600

Group type: COMPARATOR
Intervention: Information leaflet
Number of subjects: 600
Study: 22189657

Group type: EXPERIMENTAL
Intervention: S-ketamine infusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 21305729

Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab (IVB) 1.25 mg/0.05 mL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab and Triamcinolone (IVB/IVT) 1.25 mg/0.05 mL and 2 mg/0.05 mL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 60
Study: 18251159

Group type: EXPERIMENTAL
Intervention: 30‐min Pringle maneuver with gabexate mesilate (GM, 2 mg/kg/h)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 15‐min Pringle maneuver with gabexate mesilate (GM, 2 mg/kg/h)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 30‐min Pringle maneuver without gabexate mesilate (GM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 15‐min Pringle maneuver without gabexate mesilate (GM)
Number of subjects: 120
Study: 16297750

Group type: COMPARATOR
Intervention: Group B (44 patients) - Intraoperative anesthetic management was blinded to BIS values.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Group C (41 patients) - Anesthesiologist observing the BIS monitor informed the attending anesthesiologist about the BIS score.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Group A (36 patients) - Continuous access to BIS information.
Number of subjects: 121
Study: 12089888

Group type: EXPERIMENTAL
Intervention: Uroflowmetric parameters in children with urinary tract infections
Number of subjects: 379

Group type: COMPARATOR
Intervention: Control group (195 patients)
Number of subjects: 379
Study: 10816746

Group type: EXPERIMENTAL
Intervention: Permethrin-treated Olyset Net mosquito nets
Number of subjects: 0
Study: 8574280

Group type: EXPERIMENTAL
Intervention: Ephedrine (30 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nadolol (2.5 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nadolol (5 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nadolol (10 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2302146

Group type: EXPERIMENTAL
Intervention: Underpredicted pain
Number of subjects: 0
Study: 540445

Group type: EXPERIMENTAL
Intervention: Complete bed rest for 24 hours
Number of subjects: 10
Study: 31816249

Group type: EXPERIMENTAL
Intervention: erenumab 70 mg
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: erenumab 140 mg
Number of subjects: 667

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Overall erenumab-treated population
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Not achieving ≥50% response
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Not achieving ≥75% response
Number of subjects: 667
Study: 29948221

Group type: EXPERIMENTAL
Intervention: CD44 gene expression and DNA methylation levels in low responders (LR)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: CD44 protein levels measured by ELISA in human plasma
Number of subjects: 47
Study: 28763443

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic training (IHT) in a normobaric hypoxia environment (FiO2 = 15.5%)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic training (IHT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (normoxic training)
Number of subjects: 16
Study: 24761786

Group type: EXPERIMENTAL
Intervention: Social consequences framed as a loss
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Health consequences framed as a gain
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Social consequences framed as a gain
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Health consequences framed as a loss
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 124
Study: 25065452

Group type: EXPERIMENTAL
Intervention: Cognitive treatment
Number of subjects: 75

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 75
Study: 22829944

Group type: EXPERIMENTAL
Intervention: Combination of statins (rosuvastatin or atorvastatin) and regular exercise
Number of subjects: 28
Study: 19168602

Group type: EXPERIMENTAL
Intervention: Levetiracetam (250 mg/day to 2000 mg/day for 6 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 17487770

Group type: EXPERIMENTAL
Intervention: Edge-to-edge repair with De Vega annuloplasty (group E)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Modified De Vega annuloplasty alone (group D)
Number of subjects: 57
Study: 14678341

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine
Number of subjects: 16
Study: 12499479

Group type: EXPERIMENTAL
Intervention: Periodic leg movements (PLM) in idiopathic REM sleep behavior disorder (RBD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PLM features and PLMS-related cardiac activation during stage 2 sleep
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PLMS associated with microarousal
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PLMS frequency during REM sleep
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PLM mean duration and interval
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of PLMS in RBD and RLS
Number of subjects: 40
Study: 9650913

Group type: EXPERIMENTAL
Intervention: Numerical chromosome 16 aberrations in primary tumors
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Numerical chromosome 16 aberrations in metastatic tumors
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 16q deletion in primary tumors
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 16q deletion in metastatic tumors
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Loss of E-cadherin expression in primary tumors
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Loss of E-cadherin expression in metastatic tumors
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: High tumor grade and DNA aneuploidy correlation with metastases
Number of subjects: 53
Study: 8748046

Group type: EXPERIMENTAL
Intervention: GHB
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GHB + naloxone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GHB + metergoline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo + saline
Number of subjects: 10
Study: 2702460

Group type: EXPERIMENTAL
Intervention: Dressings applied until the time of suture removal
Number of subjects: 1202

Group type: COMPARATOR
Intervention: No dressings after the first postoperative day
Number of subjects: 1202
Study: 545993

Group type: EXPERIMENTAL
Intervention: Volume loading to a mean pulmonary artery occlusion pressure (MPAOP) of 16 mmHg (2.13 kPa) before declamping
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group maintained at an average MPAOP of 11 mmHg (1.46 kPa) before declamping
Number of subjects: 19
Study: 30865791

Group type: EXPERIMENTAL
Intervention: Short regimen (9 to 11 months) including high-dose moxifloxacin
Number of subjects: 424

Group type: COMPARATOR
Intervention: Long regimen (20 months) following WHO guidelines
Number of subjects: 424
Study: 27860212

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Dietary intake (fibre, carbohydrates, fat)
Number of subjects: 147
Study: 25467012

Group type: EXPERIMENTAL
Intervention: HAL hydrochloride 5%
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study: 23532799

Group type: EXPERIMENTAL
Intervention: FITNET
Number of subjects: 86

Group type: COMPARATOR
Intervention: SC
Number of subjects: 86
Study: 17317747

Group type: EXPERIMENTAL
Intervention: Healthy elderly individuals (loop gain <= 0.25)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Elderly individuals with obstructive sleep apnoea (loop gain <= 0.26)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Young individuals (loop gain <= 0.47)
Number of subjects: 14
Study: 15235926

Group type: EXPERIMENTAL
Intervention: Baked skim soy with soy sauce (protein, 86.9 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Beefsteak (200 g)
Number of subjects: 6
Study: 10980457

Group type: EXPERIMENTAL
Intervention: Regular fluticasone (250 microg twice daily for two weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Single fluticasone (250 microg 30 min before allergen inhalation)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Single placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regular placebo
Number of subjects: 10
Study: 8831994

Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells (PBSC) transplantation in AML patients
Number of subjects: 44

Group type: COMPARATOR
Intervention: Peripheral blood stem cells (PBSC) transplantation in patients with other diseases
Number of subjects: 44
Study: 1424488

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Acylureide penicillins
Number of subjects: 72
Study: 2413692

Group type: EXPERIMENTAL
Intervention: Topical indomethacin applied under occlusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Vehicle control applied under occlusion
Number of subjects: 15
Study: 31030961

Group type: EXPERIMENTAL
Intervention: 2 Hz spinal cord stimulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: α‐bungarotoxin (α7 nicotinic acetylcholine receptor antagonist)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 2 Hz spinal cord stimulation + α‐bungarotoxin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study: 30476490

Group type: EXPERIMENTAL
Intervention: ASC sheets plus PRF (group A)
Number of subjects: 4

Group type: COMPARATOR
Intervention: ASC sheets only (group B)
Number of subjects: 4

Group type: COMPARATOR
Intervention: PRF only (group C)
Number of subjects: 4

Group type: COMPARATOR
Intervention: No treatment (group D)
Number of subjects: 4
Study: 29046172

Group type: EXPERIMENTAL
Intervention: New symbology for obstacles
Number of subjects: 21

Group type: COMPARATOR
Intervention: Old symbols
Number of subjects: 21
Study: 25795717

Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusions for counts <10×10(9)/L
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temperature of at least 38°C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Days with platelet count <10×10(9)/L
Number of subjects: 0
Study: 23851346

Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg, 1‐h IV infusion) with cyclosporine (5 mg/kg, 2‐h infusion)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Morphine (0.1 mg/kg, 1‐h IV infusion) without cyclosporine (control)
Number of subjects: 14
Study: 20204535

Group type: EXPERIMENTAL
Intervention: Auto bi-level device with pressure relief during exhalation
Number of subjects: 35

Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 35
Study: 19207890

Group type: EXPERIMENTAL
Intervention: Mechanical periodontal treatment with local application of minocycline (APT)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Periodontal maintenance (PM)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Mechanical tooth cleaning (MPT)
Number of subjects: 27
Study: 16790163

Group type: EXPERIMENTAL
Intervention: Psychotherapeutic liaison service
Number of subjects: 317

Group type: COMPARATOR
Intervention: Traditional psychotherapeutic consultation
Number of subjects: 317
Study: 12735922

Group type: EXPERIMENTAL
Intervention: Smear layer removed
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Smear layer present
Number of subjects: 30

Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 30
Study: 11072773

Group type: EXPERIMENTAL
Intervention: Backpack weighing 25 kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Backpack weighing 35 kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unladen (no backpack)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gradient increase
Number of subjects: 20
Study: 9532461

Group type: EXPERIMENTAL
Intervention: Self-assessment of bleeding group (n = 172)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Self-assessment of plaque group (n = 156)
Number of subjects: 328
Study: 8256504

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination with Recombivax HB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster dose of Recombivax HB given at 3 or 4 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial response to vaccination
Number of subjects: 0
Study: 2864153

Group type: EXPERIMENTAL
Intervention: Terazosin treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31547844

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration catheter (group A, n=101)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Balloon dilatation (group B, n=103)
Number of subjects: 204
Study: 28840422

Group type: EXPERIMENTAL
Intervention: Elobixibat 10 mg
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Elobixibat 15 mg
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 27465384

Group type: EXPERIMENTAL
Intervention: Calorie Restriction (CR)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Endurance Exercise (EX)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Calorie Restriction and Exercise combined (CREX)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 52
Study: 25551953

Group type: EXPERIMENTAL
Intervention: Silk sutures
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Polypropylene sutures
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 24
Study: 22626743

Group type: EXPERIMENTAL
Intervention: Remote monitoring
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard patient management
Number of subjects: 200
Study: 20802250

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 60,000 IU i.v. bolus within 3 hours after PCI
Number of subjects: 529

Group type: COMPARATOR
Intervention: Standard medical care alone (Control)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 529
Study: 18852398

Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride, 3.75 g/d
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride, 3.75 g/d (metformin monotherapy cohort)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride, 3.75 g/d (combination therapy cohort)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study: 16088820

Group type: EXPERIMENTAL
Intervention: HAART (nevirapine, lamivudine, and zidovudine) for a median of 98 days (range, 67-222 days)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No HAART (control group)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: HAART (nevirapine, lamivudine, and zidovudine)
Number of subjects: 51
Study: 12064336

Group type: EXPERIMENTAL
Intervention: Eggshell powder-enriched supplement (group A; n=24)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Purified CaCO3-enriched supplement (group B; n=22)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo product (group C; n=27)
Number of subjects: 85
Study: 10598691

Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination (2% dorzolamide and 0.5% timolol) given twice daily
Number of subjects: 242

Group type: COMPARATOR
Intervention: Concomitant administration of 2% dorzolamide (three times daily) and 0.5% timolol (twice daily)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination (2% dorzolamide and 0.5% timolol) given twice daily during open-label extension
Number of subjects: 242
Study: 8707080

Group type: EXPERIMENTAL
Intervention: Vitamin C 1 g twice daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Allopurinol 100 mg twice daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sulphasalazine 1 g twice daily
Number of subjects: 14
Study: 1684492

Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride 0.025%, 0.05%, 0.1%, and 0.2% (topical administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride 0.1% (multiple doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride 0.1% (single application)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride
Number of subjects: 0
Study: 7067358

Group type: EXPERIMENTAL
Intervention: Loading of the whole of inspiration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Loading restricted to the initial, accelerating phase of inspiratory air flow
Number of subjects: 10
Study: 30674601

Group type: EXPERIMENTAL
Intervention: CAP‐1002 (75 million cells)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CAP‐1002
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 25